Abstract 4649: BLX-3030, a potent, selective, orally available small molecule CDK9 inhibitor for aggressive variant prostate cancers

Authors: Zhaoang li, Chenyu Lin, Kyle Medley, Hariprasad Vankayalapati, David J. Bearss

Published: 2024-03-22

DOI: 10.1158/1538-7445.am2024-4649

Source: Full article